Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea L. Durst has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analyzing accessibility and suitability of online Krabbe disease resources

    by Megan Zieber, W. Curtis Weaver, Elizabeth Felter, Lesa Brackbill, Deepa Rajan, Andrea Durst

    The impact of rare diseases, like Krabbe disease (KD), collectively affecting millions worldwide, is a public health genetics issue. Because disparities in management and prognosis are often associated with health literacy levels, patient education materials (PEMs) must be accessible to parents who frequent the internet to learn about diagnoses and follow-up. This study aimed to assess accessibility and suitability of online KD resources, using results to provide recommendations for resource improvement. A Google search was conducted utilizing common search terms to identify patient-centered KD resources. Resource content was compared against an author-developed list of essential information for families. Reviewers assessed readability, using Flesch-Kincaid (FK) and Simple Measure of Gobbledygook (SMOG) formulas, and suitability utilizing the Suitability Assessment of Materials (SAM) Tool and the Patient Education Materials Assessment Tool (PEMAT). All resources included a description, symptoms, and genetics of KD. Four resources discussed genetic counseling; two mentioned next steps. Most resources (10/12) had readability scores above the recommended sixth to eighth grade levels for PEMs. The average FK and SMOG scores were 10.6 and 12.5, respectively. Eleven of twelve resources rated ‘adequate’ or higher using the SAM Tool. PEMAT understandability and actionability scores ranged from 55.1% to 94.1% and 0% to83.3%, respectively, due to lack of graphics and interactivity. No resource met all criteria. Although easy to navigate, resources struggled using clear, common language, utilizing graphics appropriately, promoting interactivity, and presenting concrete next steps. Resource development should focus on implementing post-diagnosis action steps and improving understanding by using common terminology and graphics to promote better care of individuals with KD.

  • Open Access

    Changes in multi‐gene cancer panels for children: A 4‐year retrospective review

    by Elise G. Williams, Elena Kessler, Kristine L. Cooper, Andrea Durst, Julia Meade

    The multi‐gene panel is the most utilized genetic test to evaluate for germline cancer predisposition syndromes. However, the rate of change of commercial multigene panels is not well understood, and its value as a standalone test has also not been investigated. We conducted a retrospective chart review of the UPMC Children's Hospital of Pittsburgh Cancer Predisposition Program's genetic testing results to evaluate how multigene panels for pediatric and young adult patients with cancer have changed in size and scope from 2018 to 2022. We find that multigene panels show a trend of growing larger in number of genes included over time and explore the utility of additional genetic testing after the initial round of multi‐gene panel testing. We demonstrate heterogeneity between commercial genetic testing laboratories and their panels over time, signifying a need for equity among genetic testing panels and vigilance among physicians and genetic counselors ordering panel‐based testing.


  • Assessment of Factors Associated With the Evaluation of Children for Leukemia Predisposition Syndromes: A Retrospective Single-center Study

    by Kristen R. Msgc D’aquila, Elena Msgc Kessler, Kristine L. Cooper, Andrea Durst, Julia Meade

    Five to 10% of children with cancer are thought to have a cancer predisposition syndrome (CPS). Referral guidelines for leukemia predisposition syndromes are limited and vague, requiring the treating provider to determine whether patients should have a genetics evaluation. We evaluated referrals to the pediatric cancer predisposition clinic (CPP), the prevalence of CPS in those who elected to pursue germline genetic testing, and assessed for associations between a patient’s medical history and the diagnosis of a CPS. Data were obtained via chart review of children diagnosed with leukemia or myelodysplastic syndrome between November 1, 2017, and November 30, 2021. A total of 22.7% of pediatric leukemia patients were referred for evaluation in the CPP. Of the participants evaluated with germline genetic testing, the prevalence of a CPS was 25%. Our study was able to find a CPS in different malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome. We did not find associations between a participant with an abnormal CBC before diagnosis or hematology visit and the diagnosis of a CPS. Our study supports that a genetic evaluation should be available to all children with leukemia as medical and family history alone is not predictors of a CPS.


  • Open Access

    Public Health Genetics: Surveying Preparedness for the Next Generation of Public Health Professionals

    by Anastasia M. Jacko, Andrea L. Durst, Karen L. Niemchick, Stephen M. Modell, Amy H. Ponte

    Since the Human Genome Project’s completion in 2003, the need for increased population genetic literacy has grown exponentially. To address this need, public health professionals must be educated appropriately to serve the public best. This study examines the current state of public health genetics education within existing master of public health (MPH) programs. A total of 171 MPH Council on Education for Public Health Accreditation (CEPH)-accredited programs across the nation were identified via a preliminary internet search. The American Public Health Association (APHA) Genomics Forum Policy Committee created 14 survey questions to assess the current status of incorporating genetics/genomics education within MPH programs. Using the Qualtrics survey system through the University of Pittsburgh, a link to the anonymous survey was sent to each director’s email address obtained from their program’s website. There were 41 survey responses, with 37 finished to completion, for a response rate of 21.6% (37/171). A total of 75.7% (28/37) of respondents reported having courses containing genetics/genomics information in their programs’ coursework. Only 12.6% reported such coursework to be required for program completion. Commonly listed barriers to incorporating genetics/genomics include limited faculty knowledge and lack of space in existing courses and programs. Survey results revealed the incongruous and limited incorporation of genetics/genomics within the context of graduate-level public health education. While most recorded programs report offering public health genetics coursework, the extent and requirement of such instruction are not considered necessary for program completion, thereby potentially limiting the genetic literacy of the current pool of public health professionals.


  • Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice

    by Megan A. Czekalski, Rachelle C. Huziak, Andrea L. Durst, Sarah Taylor, Phuong L. Mai

    PURPOSE: With limitations in early detection and poor treatment response, ovarian cancer is associated with significant morbidity and mortality. Up to 25% of epithelial ovarian cancer (EOC) is related to a hereditary predisposition. Current National Comprehensive Cancer Network guidelines recommend that all individuals diagnosed with EOC be offered germline genetic testing. Although this would ideally be performed by genetics professionals, a shortage of genetic counselors can affect timely access to these services. This study sought to investigate the current genetic testing practices of oncology providers to determine the feasibility of oncologist-led genetic testing for patients with EOC. METHODS: A survey was distributed to members of the Society of Gynecologic Oncologists with questions regarding timing, frequency, and type of cancer genetic testing, referrals to genetics professionals, confidence with aspects of genetic testing, and any barriers to these processes. RESULTS: We received 170 evaluable responses. Eighty-five percent of providers always ordered genetic testing for patients with EOC. Most providers ordered germline multigene panel testing (95.8%), generally at diagnosis (64.5%). Provider confidence with the genetic testing process was generally high and significantly differed by providers' testing practices, namely, respondents who reported always ordering genetic testing tended to be more confident in ordering testing ( P = .008), interpreting results ( P = .005), and counseling a patient ( P = .002). Patient disinterest and concerns for insurance coverage were commonly cited as barriers to testing and referrals. CONCLUSION: The findings from this study suggest that oncologist-led genetic testing for patients with EOC, with referrals to genetics professionals when appropriate, has the potential to be a viable alternative service delivery model to increase access to genetic testing for patients diagnosed with EOC.


  • The impact of genetic counseling on patient engagement in a specialty cancer clinic

    by Anna L. Zakas, Claire Leifeste, Beth Dudley, Eve Karloski, Samantha Afonso, Robin E. Grubs, John R. Shaffer, Andrea L. Durst, Michael D. Parkinson, Randall Brand

    The identification of patient outcomes unique to the field of genetic counseling has become a recent priority of the profession. Current health‐care efforts have targeted patient engagement as an outcome capable of improving population health and reducing health‐care costs. This study analyzed patient engagement levels among 182 participants who underwent genetic counseling for gastrointestinal (GI) cancer risk assessment in an outpatient specialty clinic. Patients seen at the UPMC Hereditary GI Tumor Program completed a validated patient engagement measure, the Altarum Consumer Engagement (ACE), prior to undergoing genetic counseling and again three months after enrollment. Paired t test analysis was conducted to assess the changes in Total ACE scores, and within the following three domains: Navigation, Informed Choice, and Commitment. In the sample of 182 participants, Total ACE scores increased after genetic counseling (by 5.7%; p < .0001), as did all three domains (Commitment p = .0008; Navigation p = .0008; and Informed Choice p = .0016). This study is the first known report of patient engagement levels in individuals undergoing genetic counseling in a specialty cancer clinic and suggests that genetic counseling improves patient engagement levels.


  • Open Access

    The Impact of the Affordable Care Act on Funding for Newborn Screening Services

    by Julia F. Costich, Andrea L. Durst

    Objective.: The Affordable Care Act requires most health plans to cover the federal Recommended Uniform Screening Panel of newborn screening (NBS) tests with no cost sharing. However, state NBS programs vary widely in both the number of mandated tests and their funding mechanisms, including a combination of state laboratory fees, third-party billing, and other federal and state funding. We assessed the potential impact of the Affordable Care Act coverage mandate on states' NBS funding. Method.: We performed an extensive review of the refereed literature, federal and state agency reports, relevant organizations' websites, and applicable state laws and regulations; interviewed 28 state and federal officials from August to December 2014; and then assessed the interview findings manually. Results.: Although a majority of states had well-established systems for including laboratory-based NBS tests in bundled charges for newborn care, billing practices for critical congenital heart disease and newborn hearing tests were less uniform. Most commonly, birthing facilities either prepaid the costs of laboratory-based tests when acquiring the filter paper kits, or the facilities paid for the tests when the kits were submitted. Some states had separate arrangements for billing Medicaid, and smaller facilities sometimes contracted with hearing test vendors that billed families separately. Conclusion.: Although the Affordable Care Act coverage mandate may offset some state NBS funding for the screenings themselves, federal support is still required to assure access to the full range of NBS program services. Limiting reimbursement to the costs of screening tests alone would undermine the common practice of using screening charges to fund follow-up services counseling, and medical food or formula, particularly for low-income families.